© 2022 MJH Life Sciences™ and Ophthalmology Times. All rights reserved.
November 29, 2022
According to investigators, the risk for the development of dry eye disease is greater in postmenopausal women compared with those who have not reached menopause as a result of hormonal dysregulation of the ocular secretory glands.
November 21, 2022
According to the company, the OK-101 phase 2 trial will incorporate primary and secondary efficacy endpoints characterizing signs and symptoms of dry eye disease.
October 22, 2022
According to Jennifer Loh, MD, women achieve significantly better symptom relief than men.
October 04, 2022
Leading U.S. eye care experts advance eye health focused digital platform designed to make eye care part of daily self-care routine.
September 06, 2022
A potential first-in-class eye drop with a novel mechanism of action, NOV03 is an investigational therapy to treat the signs and symptoms of dry eye disease associated with Meibomian gland dysfunction.
August 24, 2022
Although predefined co-primary study endpoints were not met, AR-15512 demonstrated statistically significant improvements in DED signs, symptoms, and disease-related quality of life.
August 23, 2022
According to the company, topical eye drops anti-TNFα agent licaminlimab (OCS-02) relieve persistent ocular discomfort in severe dry eye disease.
August 16, 2022
An independent data monitoring committee recommends continuing study with a sample size target of up to 350 Patients. According to the company, no safety concerns have been identified and topline results are expected during the second quarter of 2023.
August 11, 2022
ThermaMEDx today announced a partnership with EyeCare Partners to expand EverTears distribution across the network of the national provider of clinically integrated eye care.
August 05, 2022
Tarsus Pharmaceuticals has enrolled the first patient in a Phase 2a clinical trial studying TP-03 for the treatment of meibomian gland disease in patients diagnosed with Demodex mites.